New antineoplastic for treatment of osteosarcoma

Takeda has launched Mepact (mifamurtide) for the treatment of high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection, in children, adolescents and young adults, in combination with multi-agent chemotherapy.

Mifamurtide is a potent activator of monocytes and macrophages; however, the exact mechanism by which it exerts its anti-tumour effects is not yet known.

In a Phase III study involving 678 patients aged 1.4 to 30.6 years with newly diagnosed resectable high-grade osteosarcoma, the addition of Mepact to chemotherapy (doxorubicin, cisplatin and methotrexate, with or without ifosfamide) resulted in a 28 per cent relative reduction in risk of death (p=0.0313).

View Mepact drug record

Further information: Takeda

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more